Chemo-free BRCA-targeted Neoadjuvant Strategy
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: TNBC - Triple-Negative Breast Cancer|BRCA1 Mutation|BRCA2 Mutation
Interventions: DRUG: olaparib|DRUG: Durvalumab
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Collaborators: AstraZeneca